Emerging therapies

Open studies worldwide and state-licensed programs, in one search.

Before you look

  • These are research studies and state-licensed programs. A listing is not a recommendation.
  • Ibogaine can cause dangerous heart rhythm problems, and deaths have been reported. The research.
  • Under federal law, psilocybin, MDMA, LSD, DMT and ibogaine are Schedule I drugs. Outside a registered study, Oregon and Colorado license psilocybin services under state law.
  • Ketamine is a prescription drug, and esketamine (Spravato) is FDA-approved for some forms of depression.
  • Talk with your doctor first, especially about your heart and the medicines you take. Clinics that are not licensed or part of a registered study are not listed here.
Therapy
Condition

407 results

Mapping Ibogaine Neural Dynamics in Opioid Use Disorder

Recruiting. University of California, Irvine
Irvine, California.
Ibogaine

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Recruiting. Phase 1. University of Colorado, Denver
Aurora, Colorado. 2 sites in all.
Psilocybin

Investigation to Understand and Optimize Psilocybin

Recruiting. Phase 2. Charles Raison
Edwards, Colorado.
Psilocybin

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Recruiting. Phase 1/2. Johns Hopkins University
Baltimore, Maryland.
Psilocybin

Psilocybin Therapy in Advanced Cancer

Recruiting. Phase 2/3. NYU Langone Health
Aurora, Colorado. 2 sites in all.
Psilocybin

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

Recruiting. Phase 3. VA Office of Research and Development
Birmingham, Alabama. 5 sites in all.
PsilocybinVeteran or military

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

Recruiting. Phase 2. National Institute on Aging (NIA)
Baltimore, Maryland.
Psilocybin

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Recruiting. Phase 1. University of California, Berkeley
Berkeley, California.
Psilocybin

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Recruiting. Phase early 1. Johns Hopkins University
Baltimore, Maryland.
Psilocybin

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

Recruiting. Phase 2. Icahn School of Medicine at Mount Sinai
New York, New York.
Psilocybin

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

Recruiting. Phase 1. Johns Hopkins University
Baltimore, Maryland.
Psilocybin

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

Recruiting. Phase 1/2. University of California, San Diego
San Diego, California.
Psilocybin

Psilocybin for Opioid Use Disorder (OUD)

Recruiting. Phase 2. NYU Langone Health
Albuquerque, New Mexico. 5 sites in all.
Psilocybin

Mechanistic Studies of Psilocybin in Headache Disorders

Recruiting. Phase early 1. Yale University
West Haven, Connecticut.
Psilocybin

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Recruiting. Phase 2. M.D. Anderson Cancer Center
Houston, Texas.
Psilocybin

Psilocybin for Prolonged Grief Disorder

Recruiting. Phase early 1. University of Virginia
Charlottesville, Virginia.
Psilocybin

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Recruiting. Phase 2. Yale University
New Haven, Connecticut.
PsilocybinDMT and ayahuasca

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Recruiting. Phase 2. The University of Texas Health Science Center, Houston
Houston, Texas.
Psilocybin

Open-Label Psilocybin Study in Transdiagnostic Population

Recruiting. Phase 1. Yale University
New Haven, Connecticut.
Psilocybin

Psilocybin rTMS for Treatment Resistant Depression

Recruiting. Phase 2. University of Texas at Austin
Austin, Texas.
Psilocybin

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

Recruiting. Phase 2. Sunstone Medical
Rockville, Maryland.
Psilocybin

The ENHANCE Study: taVNS and Psilocybin

Recruiting. Phase 1. University of Wisconsin, Madison
Madison, Wisconsin.
Psilocybin

Psilocybin Administration With 5-HT1a Blockade

Recruiting. Phase early 1. Johns Hopkins University
Baltimore, Maryland.
Psilocybin

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Recruiting. Phase early 1. Johns Hopkins University
Baltimore, Maryland.
Psilocybin

Mindfulness-Assisted Psychedelic Therapy

Recruiting. Phase 2. University of Southern California
Los Angeles, California.
Psilocybin